Medical Devices APAC

APAC Infectious Disease Molecular Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Infectious Disease Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Disease, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.18 Bn Placeholder estimate
Estimate 2025 $3.37 Bn 19.1% of the global market
Projected 2034 $5.69 Bn 68.9% Adds $2.32 Bn over 9 forecast years
CAGR 2025–2034 6.0% Faster than 2% of 173 Medical Devices markets here
Key players 5
  • APAC is 19.1% of the global market.
  • Among regions, the largest is North America at $8.99 Bn.
  • Fastest growing: Africa at 6.7% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.32 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Infectious Disease Molecular Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.18 Bn — —
2025 (base) $3.37 Bn +$190.7 Mn —
2026 (forecast) $3.57 Bn +$202.2 Mn +6%
2027 (forecast) $3.79 Bn +$214.3 Mn +12.4%
2028 (forecast) $4.01 Bn +$227.1 Mn +19.1%
2029 (forecast) $4.25 Bn +$240.8 Mn +26.2%
2030 (forecast) $4.51 Bn +$255.2 Mn +33.8%
2031 (forecast) $4.78 Bn +$270.5 Mn +41.9%
2032 (forecast) $5.07 Bn +$286.8 Mn +50.4%
2033 (forecast) $5.37 Bn +$304.0 Mn +59.4%
2034 (forecast) $5.69 Bn +$322.2 Mn +68.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $17.64 Bn
  2. North America $8.99 Bn
  3. US $7.64 Bn
  4. Europe $3.25 Bn
  5. APAC (this report) $3.37 Bn
  6. China $1.64 Bn
  7. Canada $1.25 Bn
  8. Japan $1.23 Bn
  9. Latin America $740.2 Mn
  10. Germany $707.8 Mn
  11. Middle East $724.6 Mn
  12. France $516.7 Mn
  13. UK $497.6 Mn
  14. Brazil $507.1 Mn
  15. Italy $475.2 Mn
  16. Ecuador $399.6 Mn
  17. Spain $292.5 Mn
  18. India $303.9 Mn
  19. Saudi Arabia $289.0 Mn
  20. Africa $259.2 Mn
  21. Mexico $243.4 Mn
  22. Australia $234.1 Mn
  23. Russia $189.8 Mn
  24. New Zealand $151.2 Mn
  25. South Africa $123.0 Mn
  26. UAE $88.7 Mn
  27. Egypt $48.2 Mn
  28. Philippines $43.0 Mn
  29. Malaysia $28.4 Mn
  30. Hong Kong $25.9 Mn
  31. Thailand $23.7 Mn
  32. Singapore $18.5 Mn
  33. Kenya $11.9 Mn

Report snapshot

APAC Infectious Disease Molecular Diagnostics Market Analysis at a glance
Market size, 2025$3.37 Bn placeholder estimate
Forecast, 2034$5.69 Bn placeholder estimate
Growth (CAGR), 2025–20346.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDisease, technology and end user (see all)
Key playersRoche Diagnostics, Abbott Laboratories, Hologic, Inc., Cepheid, bioMérieux SA (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Infectious Disease Molecular Diagnostics Market Analysis Executive Summary

Infectious disease molecular diagnostics detect the DNA or RNA of germs to diagnose infections accurately and quickly.

Key segments of the infectious Disease Molecular Diagnostics market include disease (Respiratory, HIV and Hepatitis and STIs) and technology (PCR, Isothermal and Sequencing).

Bar chart: Asia Pacific Infectious Disease Molecular Diagnostics market size, 2024–2034, placeholder estimates. $3.18 Bn in 2024, $3.37 Bn in 2025 and $5.69 Bn in 2034, 6.0% CAGR.
Asia Pacific Infectious Disease Molecular Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Infectious Disease Molecular Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the infectious Disease Molecular Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the infectious Disease Molecular Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the infectious Disease Molecular Diagnostics market.

Competitive Landscape for Infectious Disease Molecular Diagnostics Market in APAC

The infectious Disease Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Infectious Disease Molecular Diagnostics Market in APAC

Infectious Disease Molecular Diagnostics in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how infectious Disease Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Infectious Disease Molecular Diagnostics right now, from free public sources.

Latest research 35 papers since 2021 (worldwide)

  1. Oxidized phospholipids: evolution, signaling, cell death, and human diseases. Science bulletin, 2026
  2. Molecular Public Health for Infectious Disease Prevention and Control. Microorganisms, 2026
  3. Evaluation of the Biosynex AMPLIQUICK(®) Fecal Parasitology assays in a Belgian travel clinic. Frontiers in cellular and infection microbiology, 2026
  4. "Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies". Journal of inorganic biochemistry, 2026
  5. Factors Influencing Choice of Laboratory-Developed Tests and US Food and Drug Administration (FDA)-Approved or FDA-Cleared In Vitro Diagnostics for Molecular Analytes. Archives of pathology & laboratory medicine, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Infectious Disease Molecular Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Infectious Disease Molecular Diagnostics market in Asia Pacific?
Placeholder estimate: about $3.37 Bn in 2025, rising to about $5.69 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Infectious Disease Molecular Diagnostics market in Asia Pacific growing?
Placeholder estimate: about 6.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Infectious Disease Molecular Diagnostics market report cover?
The report splits the market by disease (Respiratory, HIV and Hepatitis, STIs, Tuberculosis and more), technology (PCR, Isothermal, Sequencing) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Infectious Disease Molecular Diagnostics market?
Key players include Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Cepheid and bioMérieux SA.
What is driving the Infectious Disease Molecular Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the infectious Disease Molecular Diagnostics market.
How much research is published on Infectious Disease Molecular Diagnostics?
PubMed lists 35 papers on Infectious Disease Molecular Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Infectious Disease Molecular Diagnostics in APAC? Our analysts can size it for your plan. Talk to us See the public data Medicine sales: anti-infectives for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in APAC

See all
Same topic, other categories

Related on diagnostics and lab testing and infectious diseases

See the topic